[ORGANIZATION]
Omlyclo
Featured in 5 tracked stories · first seen
Situations
Celltrion biosimilar expansions in the United States
2 clusters · 5 sources · last updated
Latest: Celltrion's Avtozma receives FDA approval for pediatric COVID-19
Celltrion has expanded its presence in the United States market through the launch and regulatory approval of multiple biosimilar products. In early October 2026, the company launched Omlyclo, the first omalizumab biosi
Celltrion pharmaceutical market expansion
2 clusters · 7 sources · last updated
Latest: Celltrion expands European biosimilar market share through new tenders
Celltrion has initiated efforts to expand its global pharmaceutical footprint through strategic partnerships and market penetration. The company announced its participation in the CPHI exhibition in Milan to seek new dru
Celltrion biosimilar market expansion
4 clusters · 6 sources · last updated
Latest: Celltrion's Remsima reaches number one in Japan's infliximab market
Celltrion continues to expand its global biosimilar market share, particularly in autoimmune and oncology treatments. In the United States, the ustekinumab biosimilar Stekyma reached a 16.2% market share in July, marking